Key Takeaways
- Roche reported solid four quarter and 2024 revenues, recovering from COVID-19 hits in 2023.
- The company is expecting pivotal trial readouts for four NMEs that could lead to drug launches in 2026.
- The company is expanding development of its anti-TLIA drug to diseases outside of IBD.
Roche is focused on building a diverse portfolio to drive long-term growth and highlighted upcoming catalysts for several late-stage programs during its fourth quarter sales and earnings call on 30 January
Roche is moving quickly to expand development of the drug, which is in a competitive class